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Background: In this study the feasibility of intensity-modulated radiotherapy (IMRT) and tomotherapy-based
image-guided radiotherapy (IGRT) for locally advanced esophageal cancer was assessed.
Methods: A retrospective study of ten patients with locally advanced esophageal cancer who underwent concurrent
chemotherapy with IMRT (1) and IGRT (9) was conducted. The gross tumor volume was treated to a median dose of
70 Gy (62.4-75 Gy).
Results: At a median follow-up of 14 months (1-39 months), three patients developed local failures, six patients
developed distant metastases, and complications occurred in two patients (1 tracheoesophageal fistula, 1 esophageal
stricture requiring repeated dilatations). No patients developed grade 3-4 pneumonitis or cardiac complications.
Conclusions: IMRT and IGRT may be effective for the treatment of locally advanced esophageal cancer with
acceptable complications.
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Treatment of locally advanced esophageal cancer re-
mains a significant challenge because of the high rate of
loco-regional and distant failures [1]. Preoperative che-
moradiation is usually advocated for better loco-regional
control in selected patients with adequate cardio-
pulmonary reserve. However, morbidity following sur-
gery remains high with a 46% rate of pulmonary and a
21% rate of cardiac complications [2]. For inoperable pa-
tients, standard of care has been concurrent chemoradi-
ation [3,4]. Radiation dose was usually limited to 50 Gy
in the U.S. because of the increased toxicity associated
with a higher dose without survival improvement [3].
However, recent studies demonstrated that high radi-
ation dose for esophageal cancer may be feasible and in
selected studies provided similar survival compared to* Correspondence: NamPhong.Nguyen@yahoo.com
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reproduction in any medium, provided the orsurgery [5-7]. Current radiotherapy techniques are lim-
ited by the radiation dose that can be safely delivered to
the gross tumor without increasing the risk of pneumon-
itis and cardiac toxicity. Thus, a radiotherapy technique
that reduces treatment toxicity while providing a cura-
tive dose of radiation to the tumor may improve survival
and local control. Intensity-modulated radiotherapy
(IMRT) has been introduced to improve target coverage
while potentially decreasing radiation dose to the normal
tissues [8-10]. Compared to three-dimensional con-
formal radiotherapy (3D-CRT), IMRT significantly re-
duced radiation dose to the heart and coronary arteries
for distal esophageal cancer [10]. The myocardium spar-
ing effect of IMRT may explain why esophageal cancer
patients treated with IMRT had less cardiac complica-
tions and better survival compared to the ones treated
with 3D-CRT [11]. A new technique of IMRT delivery,
helical tomotherapy based image-guided radiotherapy
(IGRT) provides steeper dose gradient and target cover-
age compared to conventional IMRT for patients withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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parison study, we also demonstrated that tomotherapy
provided better sparing of the heart and lungs compared
to 3D-CRT for distal esophageal cancers [13]. In the
current study, we report the clinical outcome of patients
with esophageal cancers treated with IMRT and IGRT to
assess whether these radiotherapy techniques may also
be effective for loco-regional control with acceptable
toxicity.
Methods
The medical records of 10 patients undergoing radiother-
apy for esophageal cancer at the University of Arizona
Radiation Oncology department were retrospectively iden-
tified. The University of Arizona Institutional Board (IRB)
approved the study. Prior to radiotherapy treatment, all
patients signed informed consent for radiotherapy treat-
ment, and also agreed for publication of the data, includ-
ing imaging following de-identification in the consent
form. Patients were selected if they had esophageal cancer
treated with IMRT (1) or IGRT (9) for possible cure. The
IGRT was performed with the Tomotherapy HD Unit
with daily pretreatment CT imaging. All patients received
concurrent definitive chemoradiation (8) or postoperative
chemoradiation for positive margins (2). Patients selected
for definitive chemoradiation were not candidates for re-
section because of multiple co-morbidities. Prior to treat-
ment, each patient was simulated in the supine position
with a body vacuum bag for treatment immobilization. A
computed tomography (CT) scan with and without oral
and intravenous (IV) contrast for treatment planning was
performed in the treatment position. The chest and upper
abdomen were scanned with a slice thickness of 3 mm.
The CT scan with oral and IV contrast was employed to
outline the tumor and grossly enlarged regional lymph
node for target volume delineation. Radiotherapy planning
was performed on the CT scan without contrast to avoid
possible interference of contrast density on radiotherapy
isodose distributions. Diagnostic positron emission tom-
ography (PET)-CT scan planning for tumor imaging was
also incorporated with CT planning when available. Nor-
mal organs at risk for complication were outlined for
treatment planning (spinal cord, cardiac ventricles, lungs,
kidney, liver, and bowels). The cardiac ventricles (right
and left) were contoured on the contrast CT scan. The
gross tumor volume (GTV) was outlined by integrating
information obtained from the CT scan with IV and oral
contrast study and PET-CT scan when available. Clinical
target volume (CTV) was expanded with a 0.3-0.5 cm ra-
dial expansion and a 5-cm superior-inferior expansion.
The celiac lymph nodes were also included in the CTV for
patients with cancer of the distal esophagus cancer or the
gastro-esophageal junctions with an expansion of 0.5 cm.
Any mediastinal lymph nodes enlargement observed onCT scan and/or PET scan were also included in the CTV.
The PTV was defined as 0.5 cm beyond the CTV. The inte-
grated boost technique was used for both techniques to treat
the PTV to 45 Gy at 1.8 Gy/fraction and the GTV to 50 Gy
at 2 Gy/fraction respectively. One patient had hypofractiona-
tion to the GTV at 2.2 Gray/fraction (37.4 Gy) as the PTV
as treated to 30.6 Gy at 1.8 Gy/fraction. The patient had
a very large tumor and we had to limit the total dose
delivered because of lungs constraint. Dose constraints for
normal organs at risk (OAR) for complications were:
spinal cord (Dmax <45 Gy), total lung (V5 < 50%, V10 <
40%, V15 < 30%, and V20 < 25%), cardiac ventricles (V10 <
50%), liver (V30 < 30%), kidneys (V15 < 30%), and bowels
(V45 < 50%). A minimum of 95% coverage was required
for both tomotherapy and IMRT plans. At 40 Gy to the
GTV or 37.4 Gy for the patient treated with hypofractio-
nation, a CT scan with oral and intravenous contrast was
repeated with the patient in the treatment position to as-
sess tumor shrinkage with radiation. The residual gross
tumor was boosted with a one cm margin to a achieve a
gross total tumor dose of 20 Gy in 2 Gy/fraction or 25 Gy
in 1.25 Gy twice a day (bid) for patients with definitive
chemoradiation to bring the total gross tumor dose to
70 Gy and 75 Gy respectively. The patient who had hypo-
fractionation received a GTV boost of 25 Gy in 2.5 Gy/
fraction to compensate for the lower tumor dose in the
previous treatment plan. The cumulative gross tumor
dose for that patient was 62.4 Gy. The bid boost fraction-
ation was selected in patients with tumors adherent to the
vessels or trachea to decrease the risk of complications
and in postoperative patients with positive margins to re-
duce the risks of anastomotic leaks. Among the two pa-
tients with positive margins, the former GTV was boosted
with the hyperfractionation schedule (1.25 Gy bid) to
15 Gy (cumulative gross tumor dose 65 Gy) and 20 Gy
(cumulative gross tumor dose 70 Gy). The second patient
had a higher tumor boost dose (20 Gy) because of the
delay in initiating radiotherapy after surgery.
All patients underwent concurrent chemotherapy with
5-fluorouracil (5-FU) at 1000 mg/m2/24 hours by con-
tinuous intravenous (IV) infusion on days 1-4, and
cisplatin (cisp) at 100 mg/m2 IV bolus on day 1 of radio-
therapy. Chemoradiotherapy was repeated on day 28 of
radiotherapy. Prophylactic percutaneous endoscopic
gastrostomy (PEG) feeding-tube placement was also rec-
ommended for all patients because of the expected
esophagitis and weight loss during treatment. Weekly
complete blood count (CBC) and blood chemistry work-
ups were performed during chemoradiation. Treatment
breaks and weight loss were recorded during chemoradi-
ation. Acute and long-term toxicities were graded ac-
cording to Radiotherapy Oncology Group (RTOG)
group criteria severity scales (http://www.rtog.org./).
Acute toxicity was monitored during the course of
Table 1 Patient characteristics
Patient number: 10
Age:
Range 49-75
Median 58
Sex:
Male 8
Female 2
Tumor location
Upper third 1
Middle third 2
Lower third 7
Histology
Squamous 3
Adenocarcinoma 7
Tumor stage
T3 3
T4 7
Nodal stage
N0 2
N1 5
N2 3
Treatment
IMRT 1
IGRT 9
Definitive chemoradiation 8
Postoperative chemoradiation 2
Gross tumor dose (Gy)
62.4 1
65 1
70 5
75 3
Boost technique
Hypofractionation (2.5 Gy) 1
Hyperfractionation (1.25 Gy bid) 4
Conventional fractionation (2 Gy) 5
Follow-up (months)
Range 1-38
Median 14
Gy: gray; bid: twice a day.
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tient follow-up visit.
The patients were evaluated one month after treat-
ment, every three months for two years, then every six
months for two years, then yearly. A PET-CT scan was
repeated four months, ten months, then yearly following
treatment. An endoscopic exam was repeated three to
four months after treatment, then yearly, unless there
was suspicion of local recurrences on PET-CT or clinic-
ally (dysphagia recurrence, gastrointestinal bleeding). A
repeated biopsy was performed if there was suspicion of
recurrences on endoscopic exam. All patients were mon-
itored closely by a team of dietitians during, and follow-
ing treatment to assess their nutritional status and tube
feedings. Survival analysis was performed using Kaplan-
Meier estimation.
Results
We identified 10 patients with locally advanced esopha-
geal cancer (3 T3, 7 T4) treated at the University of
Arizona Radiation Oncology department from 2008 to
2010. Median age at diagnosis was 58 years (range: 49-
75 years). There were eight males and two females. The
histology was squamous (n = 3) and adenocarcinoma
(n = 7). The tumor was located in the upper third (n = 1),
mid third (n = 2) and lower third (n = 7). Eight patients
had definitive chemoradiation and two patients had post-
operative chemoradiation. Table 1 summarizes patients
characteristics.
At a median follow-up of 14 months (range: 1-38
months), local recurrences developed in three patients.
All three recurrences occurred in the area of GTV re-
ceiving high dose of radiation within four, six, and eleven
months after radiation. Six patients developed distant
metastases (bones: 3, lungs: 1, liver: 1, abdomen and pel-
vis: 2). Two patients developed second lung primaries.
One patient died from his second primary and the other
one was salvaged with stereotactic body radiotherapy.
No patient developed regional lymph nodes recurrences.
The causes of death were local recurrence (1), distant
metastases (4), second primary (1), and pneumonia (1).
The 2-year and 3-year survival is estimated to be 50%
and 40% for the whole group.
Two patients developed grade 3-4 toxicity during
treatment (1 esophagitis and neutropenia, 1 pneumonia).
Chemotherapy was discontinued in one patient after the
first cycle because of pneumonia and one patient had
chemotherapy delayed after the first cycle because of
grade 4 neutropenia. All patients completed their radio-
therapy treatment. Only three patients had treatment
breaks ranging from 4 to 14 days. Median weight loss
was 4 kilograms (0-10 kilograms).
At a median follow-up of 14 months, two patient de-
veloped complications. One patient had esophagealstricture requiring repeated dilatations. The other patient
developed tracheoesophageal fistula requiring placement
of a stent. She eventually died from liver metastases.
Figures 1 and 2 illustrate the feasibility of tomotherapy
to deliver a high dose of radiation to the gross tumor
volume while sparing the normal heart and lungs. The
patient had a circumferential squamous cell carcinoma
Figure 1 Illustration of the dose-volume histogram of tomotherapy planning for a patient with a T4N1M0 squamous cell carcinoma
extending from the cricoid cartilage to the lower third of the esophagus. The cervical, mediastinal, and celiac lymph nodes were treated to
45 Gy in 180 Gy/fraction while the gross tumor was treated with an integrated boost technique to 50 Gy in 2 Gy/fraction. The black line
illustrates the total lung dose. Despite the large tumor size, the volume of lungs treated to 20 Gy (V20), 15 Gy (V15), 10 Gy (V10) and 5 Gy (V5)
was 18%, 25%, 38%, and 50%, respectively. Maximum spinal cord dose and brain stem dose was 37 Gy (dark blue line) and 27 Gy (light green),
respectively. The pink line illustrates the radiation dose to the cardiac ventricles. The blue and light maroon line illustrates the dose to the right
and left parotid respectively.
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and distal esophagus and invading the mediastinal lymph
nodes (T4N1M0) on PET-CT scan. The patient also had
congestive heart failure and severe chronic obstructive
pulmonary disease fromexcessive smoking and binge
drinking. He was cachectic because the tumor produced
complete obstruction of the esophagus requiring emer-
gency placement of a PEG tube for feeding. The gross
tumor and regional lymph nodes (cervical, mediastinal,
and celiac lymph nodes) were treated to 50 Gy and
45 Gy respectively with the integrated boost technique).
A repeated planning CT scan at 40 Gy demonstrated sig-
nificantreduction of the gross tumor which was then
boosted to 25 Gy in 1.25 Gy bid because of the close
proximity of the tumor to the trachea. The patient had a
complete response to the treatment on repeated endo-
scopic exam and sequential PET-CT scans. He was able
to resume oral feedings and gained weight after treat-
ment but required multiple dilatations because of
esophageal stenosis secondary to scarring. The patient
continued to smoke despite multiple medical advices
against smoking and developed a poorly differentiatedT1N0M0 carcinoma of the left upper lung lobe thought
to be a second primary three years after radiation. He is
now undergoing stereotactic body radiotherapy for sal-
vage as he is not a candidate for lobectomy because of
his medical condition.
Discussion
To our knowledge, our study confirms the feasibility of
IGRT to deliver a high dose of radiation with acceptable
complications in patients who were unable to undergo
resection because of associated co-morbidities (8) or
who had positive margins following surgery (2). Chen
et al. [14] also reported the feasibility of IGRT in 10 pa-
tients with locally advanced esophageal cancers who
were unable to undergo surgery because of disease ex-
tent and/or associated co-morbidities. However, the
gross tumor volume was only treated to 50 Gy with the
integrated boost technique similar to our study. All pa-
tients in our study had a repeated planning CT scan dur-
ing treatment to assess tumor shrinkage and the residual
tumor was boosted to improve local control. Among the
patients who had definitive chemoradiation, only one
Figure 2 Illustration of the dose-volume histogram of the tumor boost in the same patient on the planning CT repeated at 40 Gy. The
gross tumor had decreased in size significantly and was boosted to 25 Gy at 1.25 Gy twice a day to decrease the risk of complications because of
the tumor close proximity to the trachea and blood vessels. The yellow line and pink line illustrates the dose to the lungs and cardiac ventricles.
Maximum spinal cord dose was 3 Gy (orange). The brown and dark line illustrates the dose to the right and left brachial plexus.
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treatment. Using this technique, we were able to deliver
a curative dose of radiation with a conventional fraction-
ation (5), hyperfractionation (4) or hypofractionation (1)
schedule. Even though the patient number is small and
the follow-up short, only three patients recurred locally
which is encouraging because most of the patients had
locally advanced disease (7 patients T4). All local recur-
rences occurred in the GTV area receiving a high dose
of radiation emphasizing the fact that a radiation dose of
66-70 Gy may not be adequate for tumor control. As an
illustration, Bedenne et al. [5] reported a local recur-
rence rate of 43% despite a radiation dose up to 66 Gy
to the GTV in patients with esophageal cancer undergo-
ing definitive chemoradiation. In another randomized
study for patients with T3-T4 esophageal cancer under-
going chemoradiation to a total dose up to 65 Gy, loco-
regional control was achieved in only 30% of the patients
[6]. The simultaneous integrated boost (SIB) technique
allows delivery of a high dose of radiation to the gross
tumor volume and sparing of radiosensitive organs such
as the rectum in patients with prostate cancer [15]. The
adaptive radiotherapy technique by taking advantage of
the tumor shrinkage may spare the adjacent normal tis-
sues while still delivering a high radiation dose to thePTV [16,17]. As most of the recurrences following de-
finitive chemoradiation occur within the gross tumor
volume and are associated with T3-T4 lesions, current
standard radiation dose remains inadequate for local
control [18]. Other institutions reported higher gross
tumor doses ranging from 63 to 70 Gy which were well
tolerated even with the 3D-CRT technique [5-7,19].
Semrau et al. [20] reported the acute toxicity and long-
term outcome of 15 elderly esophageal cancer patients
(>70) with multiple co-morbidities who were treated
with concurrent chemoradiation to a gross tumor dose
of 63 Gy. Radiation treatment was well tolerated and
there was no difference in survival compared to younger
patients [20]. However, 3D-RT technique was associated
with significant long-term toxicities because of excessive
radiation dose to the lungs and hearts, resulting in pneu-
monitis and heart failures and/or cardiac arrythmia.
Death may ensue in long-term cancer survivors from
cardiac or pulmonary complications [19,21-23]. Elderly
patients (>75) may be at significant risk for cardiac com-
plications compared to younger patients because of the
pre-existing co-morbidities such as heart disease [23].
Thus, it is imperative for the clinicians to reduce excessive
cardiac and lungs irradiation with newer radiation modal-
ities. Intensity-modulated radiotherapy can significantly
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grade 3-4 pneumonitis in 30 patients with locally ad-
vanced esophageal cancer who underwent pre-operative
concurrent chemoradiation. Tomotherapy-based IGRT by
virtue of its steep dose gradient and daily CT imaging
allowing for reduced PTV margins may significantly de-
crease radiation dose to normal tissues and improve toler-
ance to chemoradiation in elderly cancer patients [25,26].
Nguyen et al. [13] reported significant reduction of cardiac
and lungs irradiation in a dosimetric study comparing
tomotherapy to 3D-CRT in patients with distal esophageal
cancers. Indeed, we did not observe any grade 3-4 cardiac
or pulmonary complications in our study despite the fact
that most of the patients had multiple co-morbidity fac-
tors that preclude surgery and a higher gross tumor dose.
Thus, our study corroborated the lack of serious cardiac
or lungs injury with IMRT or IGRT [11,14,24]. Indeed, a
review of the literature in esophageal cancer studies where
a higher dose of radiation was delivered to the GTV simi-
lar to our study but with the conventional 3D-CRT tech-
nique revealed a higher rate of grade 3-4 complications.
Liu et al. [27] reported the late toxicity of 111 patients with
locally advanced esophageal cancer randomized to radio-
therapy alone (n = 57) or concurrent chemoradiation (n =
54). A dose of 41.4 Gy in 1.8 Gy/fraction was delivered to
the CTV followed by a boost of 27 Gy in 1.5 Gy twice to
the GTV (total GTV dose = 68.4 Gy). Grade 3-4 toxicities
occurred in 32 patients (29%) (pulmonary fibrosis: 21,
esophageal stenosis: 10, pericarditis: 1). Five patients died
from the pulmonary fibrosis. Toita et al. [28] treated 30
patients stage I-III esophageal carcinoma with concurrent
chemoradiation. The CTV was treated to 39.6 Gy in
1.8 Gy/fraction followed by a GTV boost to achieve a total
GTV dose of 66.6 Gy. There was no death but 23 patients
(77%) developed grade 3-4 toxicities mainly hematologic
and gastrointestinal. Five patients developed deterioration
of their pulmonary function following treatment. Huzmulu
et al. [29] also corroborated the high rate of grade 3-4 tox-
icities with radiation dose escalation using the conven-
tional radiotherapy technique. 46 patients with stage II-III
esophageal cancer were treated with chemoradiation to a
total GTV dose of 66 Gy in 2 Gy/fraction. One patient
died from neutropenic septicemia. 87.5% of the patients
developed grade 3-4 toxicities. Thus, because of the large
volume of normal tissues irradiated to a higher dose of ra-
diation, toxicity of the treatment remains the limiting fac-
tor of radiation dose escalation with 3D-CRT. Welsh et al.
[30] demonstrated in a dosimetric study that radiation
dose escalation was feasible with IMRT for esophageal
cancer because of the sparing of normal organs compared
to 3D-CRT. Preliminary study of IMRT for radiation dose
escalation to 68.1 Gy to the GTV for patients with esopha-
geal cancer is promising. Only one out 20 patients devel-
oped grade 3 toxicity following chemoradiation [31]. Thelow toxicity of IMRT for radiation dose escalation in pa-
tients with esophageal cancer corroborated our results
and should be investigated in the future.
Despite the small number of patients, the study shows
the feasibility of implementing advanced concepts of
radiotherapy, notably integrating PET-CT diagnostic im-
aging and chemotherapy. In a recent review, Fokas et al.
[32] illustrate the potential of IGRT and PET-CT-based
radiotherapy planning to further improve the therapeutic
ratio of concurrent chemoradiation for esophageal can-
cer. Our study illustrates the validity of this concept that
needs to be corroborated in future prospective studies.
The limitations of our study include the heterogeneity
of our patients (widely different doses and fractionation;
definitive and postoperative chemoradiotherapy; various
anatomic tumor locations; different tumor histologies),
small number of patients and lack of GTV volume infor-
mation. However, the heterogeneity reflects a real life
situation as advanced esophageal cancer covers a wide
range of different patients and tumor biology. Beyond
the scope of our study, the key issue in future trials will
be to address what should be the major stratifying fac-
tors that would need to be taken into account.
Conclusion
Intensity-modulated and image-guided radiotherapy may
provide curative dose of radiation in patients with locally
advanced esophageal cancer with acceptable complica-
tions despite pre-existing co-morbidities. Prospective
studies with a large number of patients should be per-
formed to assess the effectiveness of these new radio-
therapy techniques to improve loco-regional control and
patient quality of life.
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